Free Biopharma Daily Stock Updates - 04/23/21

$XBI $134.30 -0.2%

Want to access our searchable Catalyst Calendar of over 1,000 biotech stock events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Covid Updates

$INO -25% US govt will not fund Ph3 due to increased EUA vaccines in the U.S. Ph3 trial to be ex-US. source


$VRNA -3.8% Pilot study results reported for Ensifentrine trial in COVID-19 hospitalized patients. source


Pipeline Updates

$ADCT -4.6% ZYNLONTA approved by FDA to treat r/r DLBCL. source


$ARNA +0.2% Etrasimod patient reported outcomes data from Phase 2b trial presented. source


$CHRS +1.8% Toripalimab achieves primary endpoints of progression free survival and overall survival. source


$TARA -18.4% Received FDA feedback for TARA-002 trial; plan to initiate pediatric trial in H2 2021. source


$NVAX +0.2% Matrix-M Phase 2b trial results published in The Lancet and initiated Phase 3 trial. source


$CALT +5.0% Nefecon granted accelerated assessment procedure by CHMP. source


$GLPG -1.2% Submitted NDA in Japan for approval of filgotinib to add UC indication to label. source


$ANAB +3.5% FDA approves JEMPERLI for DMMR endometrial cancer. source


$RMTI +13.9% Present data on Iron Deficiency Anemia Management at NHIA 2021 conference. source


Finance Updates

$JAGX +12.5% Webcast interview of company's founder, president, and CEO. source


$OCGN +3.7% Entered into agreements with investors for sale of 10 million shares of common stock. source

0 comments